Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex vs Bevacizumab in Persistent Diabetic Macular Edema
NCT02036424Phase 4Completed
- Sponsor
- Raj K. Maturi MD
- Start
- Jan 2014
- Primary completion
- Aug 2015
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Raj K. Maturi MD. Primary endpoints: Mean Visual Acuity Change at 7 months and Change in Optical Coherence Tomography Central Subfield Thickness at 7 months. Started Jan 2014; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02036424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036424.